Cns Pharmaceuticals, Inc. · NASDAQ:CNSP
Cns Pharmaceuticals — Investor Presentation (December 2021)
23 slides from Cns Pharmaceuticals's investor presentation, Dec 3, 2021
Slide 1: www.cnspharma.com 2100 West Loop South, Suite Houston, TX 77027 (800) 946 - 9185 December
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP December 2021
Slide 2: Forward-Looking Statements
CNS pharmaceuticals 2 Forward - Looking Statements This presentation incorporates information from materials filed with the SEC and contains forward - looking statements . All statements contained herein other than statements of historical fact, including statements regarding our future results of o
Slide 3: Corporate Overview
CNS pharmaceuticals 3 Corporate Overview
Slide 4: Investment Highlights
CNS pharmaceuticals 4 Investment Highlights • Developing anti - cancer drug candidates for the treatment of primary and metastatic brain and CNS cancer • Two lead programs initially developed by Dr. Waldemar Priebe, Professor of Medicinal Chemistry at The University of Texas MD Anderson Cancer Cente
Slide 5: Oncology Pipeline
CNS pharmaceuticals 5 Oncology Pipeline PRODUCT SPONSOR INDICATION RESEARCH PRECLINICAL PHASE 1 PHASE 2 Berubicin CNS GBM (Global, adults) Berubicin WPD* GBM (EU, adults) Q1 2022 Initiate Phase 2 Berubicin WPD* GBM (EU, pediatric) Q1 2022 Initiate Phase 1 Berubicin CNS Metastatic Lung & Breast, CNS
Slide 6: Management Team
CNS pharmaceuticals 6 Distinctive record of business successes and more than 15 years of experience managing the operations, strategies and finances of public and private companies. PRESIDENT & CHIEF EXECUTIVE OFFICER John M. Climaco , Esq Board certified hematologist/medical oncologist with extensi
Slide 7: Scientific and Clinical Advisors
CNS pharmaceuticals 7 Dr. Priebe is a Professor of Medicinal Chemistry in the Section of Immunobiology and Drug Carriers in the Department of Bioimmunotherapy at The University of Texas MD Anderson Cancer Center. Dr. Priebe is the inventor of more than 50 patents and the author of more than 200 scie
Slide 8: Berubicin Overview
CNS pharmaceuticals 8 Berubicin Overview
Slide 9: Executive Summary: Berubicin
CNS pharmaceuticals 9 Executive Summary: Berubicin NOVEL ANTHRACYCLINE CANDIDATE FOR THE TREATMENT OF SEVERAL SERIOUS ONCOLOGY INDICATIONS: GBM and Beyond in Other CNS Cancers • Encouraging data from Phase 1 study (44% of Phase 1 patients obtained clinical benefit of stable disease or better; this o
Slide 10: Glioblastoma Multiforme (GBM)
CNS pharmaceuticals 10 Glioblastoma Multiforme (GBM) 1: https://braintumor.org/take - action/about - gbm/ 2: 8 Major Markets includes USA, France, Germany, Italy, Spain, UK, Japan and urban China 3: Global Data, “Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027” (2017) One o
Slide 11: Berubicin Mechanism of Action
CNS pharmaceuticals 11 BERUBICIN IS THE FIRST ANTHRACYCLINE TO APPEAR TO CROSS THE BLOOD - BRAIN BARRIER AND IS DESIGNED TO CONCENTRATE IN TUMOR TISSUE WITHIN THE BRAIN Berubicin for the Treatment of GBM Mechanism of Action Berubicin has selective uptake in tumor tissue and high brain concentration
Slide 12: Demonstrated Clinical Response in GBM
CNS pharmaceuticals 12 Demonstrated Clinical Response in GBM * This does not always mean the cancer is cured. Also called a complete remission: www.cancer.gov/publications/dictionaries/cancer - terms/def/complete - response 6 MO. POST - TREATMENT Berubicin Phase 1 Results PRE - TREATMENT • 44% subje
Slide 13: Potentially Pivotal Study
CNS pharmaceuticals 13 Potentially Pivotal Study • Dose Berubicin 7.1 mg/m2 IV infusion vs. Lomustine 130 mg/m2 oral • Clinical Sites ~60 centers across; North America, Europe and Asia Pacific • Primary Endpoint Overall Survival (OS) • Secondary Endpoints Duration of Response ( DoR ); Objective Resp
Slide 14: Open Label Phase Study in Europe
CNS pharmaceuticals 14 Open Label Phase 2 Study in Europe Adult Study Expected to Commence 1Q 2022 • Dose Berubicin 7.1 mg/m2 IV infusion • Primary Endpoint Objective Response Rate (ORR) • Secondary Endpoints Duration of Response ( DoR ); Overall Survival (OS); Individual components of the ORR (CR/P
Slide 15: Expansion Into Other Cancers
CNS pharmaceuticals 15 Expansion Into Other Cancers INDICATION PATIENT POPULATION ESTIMATED U.S. PATIENTS COMMENTS Primary Brain Tumors Relapsed High Grade Gliomas 15,000 Existing data in this population Brain Metastases - Combination with Radiation Therapy Small Cell Lung Cancer 56,500 Anthracyclin
Slide 16: Intellectual Property
CNS pharmaceuticals 16 Intellectual Property Berubicin • Berubicin’s primary protection is currently the Orphan Drug Designation which provides marketing exclusivity in US market for 7 - years post NDA approval • Additional protection is offered as a New Chemical Entity • CNS is exploring potential
Slide 17: Lead Compound: Berubicin
CNS pharmaceuticals 17 Lead Compound: Berubicin NOVEL ANTHRACYCLINE CANDIDATE FOR THE TREATMENT OF SEVERAL SERIOUS ONCOLOGY INDICATIONS x 44% OF PHASE 1 PATIENTS (AND 49% OF AVASTIN - NAÏVE PATIENTS) OBTAINED CLINICAL BENEFIT OF STABLE DISEASE OR BETTER x ONE COMPLETE RESPONDER FROM PHASE 1 REMAINS
Slide 18: Remaining Pipeline and Value Driving Milestones
CNS pharmaceuticals 18 Remaining Pipeline and Value Driving Milestones
Slide 19: WP1244 / WP1874
CNS pharmaceuticals 19 WP1244 / WP1874 TECHNOLOGY ORIGINALLY DEVELOPED AND LICENSED FROM THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER • CNS licensed the WP1244 patent portfolio which now includes WP1874, a new formulation which includes a different salt to increase solubility and improve stabil
Slide 20: Value Driving Milestones
CNS pharmaceuticals 20 Value Driving Milestones Berubicin Development in the U.S. x Orphan Drug Designation June 2020 x IND Accepted for Berubicin Dec. 2020 x Initiated Potentially Pivotal Global Berubicin trial for GBM May 2021 x Fast Track Designation June 2021 x Patient Dosing in Potentially Pivo
Slide 21: Financial Snapshot
CNS pharmaceuticals 21 Financial Snapshot Market Cap 1 ~$30.4M 1: As of November 30, 2021; 2: As of November 12, 2021 NASDAQ: CNSP IPO $9.8M November 7, 2019 Shares Outstanding 2 ~27.9M Average Volume 1 ~201K Cash Balance $8.3M As of September 30, 2021
Slide 22: Investment Summary
CNS pharmaceuticals 22 Investment Summary DEVELOPING A PIPELINE OF ANTI - CANCER DRUG CANDIDATES FOR THE TREATMENT OF BRAIN CANCERS, AN AREA IN NEED OF NEW INNOVATIONS Multiple value - driving milestones expected throughout 2021 and 2022 1 Lead program, Berubicin, in ongoing potentially pivotal stud
Slide 23: www.cnspharma.com 2100 West Loop South, Suite Houston, TX 77027 (800) 946 - 9185
www.cnspharma.com 2100 West Loop South, Suite 900 Houston, TX 77027 (800) 946 - 9185 NASDAQ: CNSP
CNS Pharmaceuticals — Investor Presentation (December 2021) on 6ix